Table 1. Clinical characteristics of... | Rockefeller University Press

Table 1.

Clinical characteristics of patients with CAPS

Syndrome	Sex	Mutation	Age (yr)	Treatment	Figure
MWS	M	T436A	32	Canakinumab	Fig. S1, E–H
FCAS	F	L353P	86	Rilonacept	Fig. S1, E–H
FCAS	F	L353P	32	Rilonacept	Fig. S1, E–H
NOMID	M	G326E	13	Anakinra	Fig. S2, G–I
MWS	F	R260W	42	Canakinumab	Fig. S2, G–I
FCAS	F	L353P	74	Canakinumab	Fig. S2, G–I
FCAS?	F	V198M	46	–	Fig. S2 J
FCAS	M	A439V	48	Canakinumab	Fig. 3 E
MWS	F	Q567K	70	–	Fig. S2 J

Syndrome	Sex	Mutation	Age (yr)	Treatment	Figure
MWS	M	T436A	32	Canakinumab	Fig. S1, E–H
FCAS	F	L353P	86	Rilonacept	Fig. S1, E–H
FCAS	F	L353P	32	Rilonacept	Fig. S1, E–H
NOMID	M	G326E	13	Anakinra	Fig. S2, G–I
MWS	F	R260W	42	Canakinumab	Fig. S2, G–I
FCAS	F	L353P	74	Canakinumab	Fig. S2, G–I
FCAS?	F	V198M	46	–	Fig. S2 J
FCAS	M	A439V	48	Canakinumab	Fig. 3 E
MWS	F	Q567K	70	–	Fig. S2 J

F, female; M, male; NOMID, neonatal-onset multisystem inflammatory disease.